During the Revolutionizing Atopic Dermatitis (RAD) June 2024 meeting, presenters showcased how ruxolitinib cream, a topical Janus kinase 1/JAK2 inhibitor, is the first US Food and Drug Administration and European Commission-approved...
During the Revolutionizing Atopic Dermatitis (RAD) June 2024 meeting, presenters showcased how ruxolitinib cream, a topical Janus kinase 1/JAK2 inhibitor, is the first US Food and Drug Administration and European Commission-approved...
During the Revolutionizing...